An expanded access record providing ITM-11 in Meningioma, sponsored by ITM Solucin GmbH. Available. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by ITM Solucin GmbH · Expanded access
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Expanded Access Program (EAP) is intended to provide eligible participants with access to ITM-11 prior to approval by local regulatory authorities. Program availability is subject to country eligibility. The treating physician must determine, based on the individual patient´s medical history and the program eligibility criteria, whether the potential benefits outweigh the risks of treatment with an investigational therapy.
256 studies on the registry are indexed under Meningioma; 86 are open to participants now.
Browse Meningioma studies →ITM Solucin GmbH is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-
Exclusion Criteria:
-
Intravenous (IV) infusion
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ITM Solucin GmbH